Pharmacological Treatment in Hand Osteoarthritis

Phase 3

Completed

• Conditions: gewrichtaandoening; degenerative arthritis; degenerative joint disease

• Registration Number: NL-OMON38184
• Lead Sponsor: Maasstadziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

Age * 40 years
Primary hand OA according to the ACR classification
Heberden or Bouchard nodule or Kellgren-Lawrence grade 1, 2 or 3 in * 2 symptomatic joints
Pain in the dominant hand * 12 months
Use of an NSAID for * 1 episode of pain
Written informed consent

Exclusion Criteria

Secondary hand OA, e.g. hemochromatose, rheumatoid arthritis, posttraumatic
Kellgren-Lawrence grade 4 OA
Use of hydroxychloroquine within 3 months before entering the study
Use of NSAIDs or corticosteroids within 7 days before entering the study
Retinopathy
Myastenia Gravis
Known allergy or hypersensitivity for hydroxychloroquine

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pain intensity at week 24 (100 mm VAS) compared to baseline</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Hand function at week 24 (AUSCAN and AIMS2-SF) compared to baseline<br /><br>Pain intensity at week 6 and 12 compared to baseline<br /><br>Radiographic progression at week 24</p><br>